Endocrinology, Diabetes & Metabolism Doctors in Gettysburg, PA Accepting Medicare

6 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 6

Nesreen Sayed Awad Elkariem Hag Ahmed, Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 40 V Twin Dr Ste 205, Gettysburg, PA 17325 Phone: 717-339-2790    Fax: 717-798-3162

Muhammad Badshah, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 40 V Twin Dr Ste 205, Gettysburg, PA 17325 Phone: 717-339-2790

Nargess Kaviani, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 40 V Twin Dr Ste 205, Gettysburg, PA 17325 Phone: 717-339-2790    Fax: 717-798-3162

Jhansi Lakshmi Ganji, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 40 V Twin Dr Ste 205, Gettysburg, PA 17325 Phone: 717-339-2790    Fax: 717-798-3162

Ashok K Kuruvilla, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 40 V Twin Dr, Suite 205, Gettysburg, PA 17325 Phone: 717-339-2790    Fax: 717-339-2771

Dr. Brian E Michael, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 20 Expedition Trl, Ste 201, Gettysburg, PA 17325 Phone: 316-644-0318

News Archive

Study shows effect of vitamin E on pneumonia risk in older men may depend on lifestyles

Many people have been advised to take vitamin supplements to boost their immune systems.

Takeda begins MLN9708 phase 3 clinical trial in newly diagnosed myeloma patients

Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating once a week MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are not candidates for transplant.

First patient included in the phase II study of Amphinex® in head and neck cancer patients

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).

WHO member states approve new treaty to fight illegal tobacco trade

WHO member states meeting in Seoul, South Korea, on Monday unanimously approved a new international treaty to combat the illegal tobacco trade, VOA News reports.

OHSU, Intel team up to develop technologies to make personalized genomic analysis faster

Oregon Health & Science University and Intel Corp. are teaming up to develop next-generation computing technologies that advance the field of personalized medicine by dramatically increasing the speed, precision and cost-effectiveness of analyzing a patient's individual genetic profile.

Read more Medical News

› Verified 1 days ago